- Business Wire•11 months ago
Burzynski Research Institute, Inc. Announces the Launch of a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma
Burzynski Research Institute, Inc. announced today that it has begun patient enrollment into an FDA-reviewed and IRB-approved, open-label, single-arm phase 2 study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma .
- Accesswire•last year
NEW YORK, NY / ACCESSWIRE / January 4, 2016 / BioTechstocks.com - Brain tumors are among the most difficult to treat cancers in the oncology space. Their tendency for late stage diagnosis, and the difficulty ...
We're sorry this is all we were able to find about this topic.
BZYR : Summary for BURZYNSKI RESEARCH COM USD0.001 - Yahoo Finance
Burzynski Research Institute, Inc. (BZYR)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.00 - 0.00|
|52 Week Range|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-7.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|